undamentalytics Newsletter
Sign in

Humacyte, Inc. cash flow statement

In fiscal 2025, Humacyte, Inc.'s operations generated −$105m of cash; it spent $884,000 on capital projects, leaving free cash flow of −$106m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−98−105−97
Depreciation and amortisation555
Stock-based pay61011
Capital spending210
Free cash flow−100−106−98
Free cash flow after stock pay−106−116−108

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: HUMA vs KRSACLGN vs HUMAHUMA vs KRRO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Humacyte, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Humacyte, Inc.